Cuong Do
Founding Partner of SIP
Global Consortium Member
Innovation Challenge Mentor
Biography
Cuong Do, MBA, currently serves as the President and CEO of BioVie Inc. BioVie (NASDAQ: BIVI) is a clinical-stage company developing innovative therapies to overcome unmet medical needs in chronic debilitating conditions. Cuong and his team are focused on the research and developments in the treatment of advanced liver disease and neurological and neurodegenerative disorders. Prior to his appointment with BioVie, Cuong Do was the President of Samsung Global Strategy Group where he helped to set the strategic direction for Samsung Group’s diverse business portfolio. He also previously the Chief Strategy Officer for Merck, a leading U.S. pharmaceuticals company. Mr. Do is a former senior partner at McKinsey & Company, where he spent 17 years helping to build the healthcare, high tech and corporate finance practices. He holds a BA from Dartmouth College, and an MBA from the Tuck School of Business at Dartmouth.
BioVie's Clinical Research & Drug Development
In neurodegenerative disease, BioVie’s drug candidate NE3107 inhibits inflammatory activation of ERK and NFkB (e.g., TNF signaling) that leads to neuroinflammation and insulin resistance, but not their homeostatic functions (e.g., insulin signaling and neuron growth and survival). Both are drivers of Alzheimer’s and Parkinson’s diseases. BioVie is conducting a potentially pivotal Phase 3 randomized, double blind, placebo controlled, parallel group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer’s disease (NCT04669028) and is targeting primary completion in mid-2023. An estimated six million Americans suffer from Alzheimer’s. A Phase 2 study of NE3107 in Parkinson’s disease (NCT05083260) is enrolling patients and expects to have topline data readout by the end of 2022.
In liver disease, BioVie’s Orphan drug candidate BIV201 (continuous infusion terlipressin), with FDA Fast Track status, is being evaluated in a US Phase 2b study for the treatment of refractory ascites due to liver cirrhosis with top-line results anticipated in mid-2023. BIV201 is administered as a patent-pending liquid formulation. The active agent is approved in about 40 countries for related complications of advanced liver cirrhosis but is not available in the US or Japan. To learn more, visit www.bioviepharma.com.